- Home
- CNS vs TGTX Comparison
CNS vs TGTX Comparison
Compare CNS & TGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CNS
- TGTX
- Stock Information
- Founded
- CNS 1986
- TGTX 1993
- Country
- CNS United States
- TGTX United States
- Employees
- CNS N/A
- TGTX N/A
- Industry
- CNS Investment Managers
- TGTX Biotechnology: Pharmaceutical Preparations
- Sector
- CNS Finance
- TGTX Health Care
- Exchange
- CNS Nasdaq
- TGTX Nasdaq
- Market Cap
- CNS 4.7B
- TGTX 5.4B
- IPO Year
- CNS 2004
- TGTX 1995
- Fundamental
- Price
- CNS $94.55
- TGTX $33.50
- Analyst Decision
- CNS Hold
- TGTX Strong Buy
- Analyst Count
- CNS 3
- TGTX 6
- Target Price
- CNS $92.00
- TGTX $40.67
- AVG Volume (30 Days)
- CNS 196.6K
- TGTX 1.9M
- Earning Date
- CNS 01-22-2025
- TGTX 11-04-2024
- Dividend Yield
- CNS 2.50%
- TGTX N/A
- EPS Growth
- CNS 0.80
- TGTX N/A
- EPS
- CNS 2.68
- TGTX N/A
- Revenue
- CNS $496,822,000.00
- TGTX $264,790,000.00
- Revenue This Year
- CNS $7.00
- TGTX $44.11
- Revenue Next Year
- CNS $17.56
- TGTX $63.92
- P/E Ratio
- CNS $35.26
- TGTX N/A
- Revenue Growth
- CNS 0.21
- TGTX 39.53
- 52 Week Low
- CNS $64.13
- TGTX $12.84
- 52 Week High
- CNS $110.67
- TGTX $36.84
- Technical
- Relative Strength Index (RSI)
- CNS 39.66
- TGTX 56.43
- Support Level
- CNS $89.29
- TGTX $30.41
- Resistance Level
- CNS $101.73
- TGTX $32.78
- Average True Range (ATR)
- CNS 2.63
- TGTX 1.76
- MACD
- CNS -0.68
- TGTX -0.24
- Stochastic Oscillator
- CNS 39.61
- TGTX 66.88
About CNS Cohen & Steers Inc
Cohen & Steers is a niche asset manager concentrating on real estate securities. The firm invests mainly in the equity shares of real estate investment trusts, with holdings in domestic and international real estate securities accounting for close to two thirds of its $79.3 billion in managed assets at the end of January 2024. Cohen & Steers also manages portfolios dedicated to preferred securities, utilities stocks, and other high-yield offerings. The firm's distribution is balanced among its closed-end funds, open-end funds, and institutional accounts. During the past four calendar quarters, the company garnered 42% (27%) of its managed assets (base management fees) from institutional clients, 45% (52%) from open-end funds, and 13% (21%) from closed-end funds.
About TGTX TG Therapeutics Inc.
TG Therapeutics Inc is a fully integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). and the company is developing TG-1701 (BTK inhibitor) and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders which are under Phase 1 trial.